Log in to your Inderes Free account to see all free content on this page.
Nanexa
0.96 SEK +2.35%3 investors are following this company
Nanexa is a drug delivery company with a proprietary platform that is used for the formulation of injectable depot drugs that create a supply of drugs to the blood. The PharmaShell process is based on ALD (Atomic Layer Deposition) technology, which encloses pharmaceutical particles with a thin shell and creates opportunities for pharmaceutical companies to develop new products. Nanexa has cooperation with several pharmaceutical companies, mainly around the Nordic market.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
NANEXA
Daily low / high price
0.94 / 0.97
SEK
Market cap
130.27M SEK
Turnover
70K SEK
Volume
74K
Financial calendar
Interim report
27.08.2024
Interim report
07.11.2024
Annual report
19.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Novo Nordisk A/S | 19.9 % | 19.9 % |
Avanza Pension | 5.7 % | 5.7 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
First patient dosed in Nanexa's Phase I trial of NEX-22 in type 2 diabetes
Bulletin from Nanexa’s Annual General Meeting
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio